Medpace Holdings, Inc. (NASDAQ:MEDP) Given Consensus Rating of “Hold” by Analysts

Medpace Holdings, Inc. (NASDAQ:MEDP) has been given an average rating of “Hold” by the seventeen ratings firms that are presently covering the firm, MarketBeat reports. Four research analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation, two have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $490.8182.

MEDP has been the subject of a number of recent research reports. Robert W. Baird set a $613.00 target price on Medpace in a research report on Friday, October 24th. Barclays lifted their price target on shares of Medpace from $485.00 to $525.00 and gave the stock an “underweight” rating in a research note on Monday, December 15th. BMO Capital Markets initiated coverage on shares of Medpace in a report on Thursday, November 13th. They issued a “market perform” rating and a $600.00 price objective for the company. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, December 20th. Finally, Rothschild & Co Redburn cut shares of Medpace from a “buy” rating to a “neutral” rating and lifted their target price for the stock from $342.00 to $474.00 in a research report on Wednesday, September 3rd.

Insider Transactions at Medpace

In other news, VP Susan E. Burwig sold 20,000 shares of the business’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $609.15, for a total value of $12,183,000.00. Following the completion of the sale, the vice president owned 27,500 shares of the company’s stock, valued at approximately $16,751,625. The trade was a 42.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, President Jesse J. Geiger sold 21,503 shares of the stock in a transaction dated Wednesday, November 5th. The shares were sold at an average price of $595.66, for a total value of $12,808,476.98. Following the sale, the president owned 15,000 shares of the company’s stock, valued at $8,934,900. This represents a 58.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 387,925 shares of company stock worth $233,386,647. Company insiders own 20.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in MEDP. Quent Capital LLC bought a new stake in Medpace during the 3rd quarter valued at $25,000. Optiver Holding B.V. purchased a new position in shares of Medpace in the third quarter valued at about $27,000. Geneos Wealth Management Inc. raised its stake in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after acquiring an additional 37 shares during the last quarter. Quarry LP bought a new position in shares of Medpace during the third quarter valued at about $35,000. Finally, Employees Retirement System of Texas purchased a new stake in shares of Medpace during the second quarter worth about $36,000. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $567.56 on Friday. The firm has a market capitalization of $15.99 billion, a PE ratio of 39.69, a price-to-earnings-growth ratio of 2.14 and a beta of 1.43. Medpace has a 52-week low of $250.05 and a 52-week high of $626.26. The firm has a fifty day moving average of $579.62 and a 200 day moving average of $481.39.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, beating analysts’ consensus estimates of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The business had revenue of $659.90 million for the quarter, compared to the consensus estimate of $640.49 million. During the same quarter last year, the business posted $3.01 earnings per share. The company’s revenue for the quarter was up 23.7% on a year-over-year basis. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. On average, sell-side analysts forecast that Medpace will post 12.29 EPS for the current fiscal year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.